Track efinopegdutide in Peptimes™
Efinopegdutide is an investigational oxyntomodulin analogue joined by a polyethylene glycol (PEG) linker to part of a human antibody (an IgG4 Fc fragment), according to FDA's substance registry. (Source: FDA's substance registry (GSRS).)
Is efinopegdutide FDA-approved?
No. Efinopegdutide is investigational: it's being studied in clinical trials and isn't FDA-approved for any use.
Efinopegdutide
Also: MK-6024, HM12525A, JNJ-64565111, LAPS-GLP/GCG
- Status label in the Peptimes Library
- Phase 2 Trials
- Routes in Peptimes
- Subcutaneous
- Updated
- 1 Nov 2026
US regulatory status
FDA status
Not FDA-approved for any use. Drugs@FDA lists no application with efinopegdutide as an active ingredient.
Source: Drugs@FDA, checked 1 Nov 2026
Investigational
Yes.
Source: ClinicalTrials.gov, checked 1 Nov 2026
How to track it in Peptimes
Add efinopegdutide in My Protocols and set the schedule you already follow: days of the week, times of day and a start date. Peptimes never suggests an amount when you log or schedule a dose. Its Library entry shows the status label “Phase 2 Trials”, which describes its investigational status. It isn’t an approval.
- Logging: the amount you took and how you feel.
- Injection sites: each dose records the site, and Insights shows where you’ve injected and how recently. It never suggests where to inject next.
- Reminders and history: reminders at your times, Dose History, the Calendar and CSV or JSON export work as described on the peptide tracker app page.
Peptimes is a tracking app, not medical advice. Talk to a licensed clinician about your treatment. Peptimes doesn’t sell efinopegdutide or any other compound.
More sources
- NIH, ClinicalTrials.gov, studies of efinopegdutide, checked 1 Nov 2026: registered studies, Phase 1 and Phase 2, sponsored by Merck Sharp & Dohme.
- NIH, ClinicalTrials.gov, NCT06482112, checked 1 Nov 2026: a completed Phase 2 study of efinopegdutide (MK-6024).
- FDA, Drugs@FDA, searched 1 Nov 2026: no application lists efinopegdutide as an active ingredient.
- FDA, Global Substance Registration System, Efinopegdutide, checked 1 Nov 2026: its structure and the codes HM12525A, JNJ-64565111 and LAPS-GLP/GCG.